Halozyme (HALO)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$110.19-0.51%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · HALO
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -6.9% |
| Our one-year growth estimate | diamond | 17.1% |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
Usually moved in the same direction.
Price observations: 365 days
Most sensitive to the broad stock market.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
A larger daily loss that occurred about once in every 20 trading days.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Growth built into the price is above our model estimate.
The price assumes 24.0 percentage points less one-year growth.
The one-year revenue growth assumption on Valuation.
Model as of 2026-09-04 · Compared with 398 industry peers · Company calendar date is not available
HALO — director transition
Dated 2026-08-18
Director — Dannielle Appelhans: The filing discloses the election of a new director to the board, which is a routine governance event and not a departure of a senior executive.
Why it matters: This acquisition may improve Halozyme's drug delivery. It could also create new revenue sources.
Supportive ifThe Elektrofi acquisition will close as planned by Q4 2025.
Worry ifThe acquisition faces delays or fails to close by Q4 2025.
Why it matters: Cash from operations is vital for funding growth. A decline could signal financial strain.
Worry ifCash from operations falls below $180 million in Q3.
Less concerning ifCash from operations remains above $180 million in Q3.
Why it matters: Slower growth in operating income may mean higher costs or less efficiency.
Worry ifOperating income growth slows to below 70% year over year.
Less concerning ifOperating income growth remains at or above 70% year over year.
Why it matters: A new CFO can change how money is managed. This affects how the company talks to investors.
Watch forDarren Snellgrove starts new money management strategies. These help the company work better with investors.
Also watch forThere are no clear changes in money management or investor relations after the CFO change.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$134 on $10,000 · ±1.3% | How much price usually moves either way. |
| Bad day | $282 loss on $10,000 · 2.8% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $2,413 loss on $10,000 · 24.1% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: Finishing this program shows strong cash flow. It also shows management cares about shareholders.
Supportive ifHalozyme completes at least $400 million in share repurchases by the end of 2026.
Worry ifShare repurchases fall short of $400 million by the end of 2026.
Why it matters: Better operating income means Halozyme is controlling costs well. This is important for making money long-term.
Supportive ifOperating income increases by more than 10% in Q2 compared to Q1.
Worry ifOperating income does not improve or declines in Q2 compared to Q1.
Why it matters: New partnerships would show strong interest in Halozyme's technologies. This would help make more money.
Supportive ifAt least one new partnership or licensing deal is announced by the end of 2026.
Worry ifNo new partnerships or licensing deals are announced by the end of 2026.
Why it matters: Hitting this growth target would show that Halozyme's plan is working. It would also show that management cares about making more money.
Supportive ifTotal revenue for 2026 reported at or above $1.710 billion.
Worry ifTotal revenue for 2026 is below $1.710 billion.
Why it matters: Total revenue growth shows if Halozyme can keep its strong performance going. A solid growth rate supports investor confidence.
Supportive ifQ3 2026 total revenue growth above 30% year over year.
Worry ifQ3 2026 total revenue growth below 22% year over year.
Why it matters: New products could drive significant royalty revenue starting in 2029 and beyond.
Supportive ifHalozyme will announce new ENHANZE products in development, bringing the total to 13 by the end of 2026.
Worry ifHalozyme fails to meet the target of 13 ENHANZE products in development by year-end 2026.
Why it matters: New partnerships can help Halozyme make more money. More collaborations show growth potential.
Supportive ifAt least two new collaboration agreements will be announced in Q3 2026.
Worry ifNo new collaborations will be announced in Q3 2026.
Why it matters: This may show a slowdown in Halozyme's revenue growth. This could hurt investor confidence.
Worry ifQ2 total revenue growth reported below 22% year over year.
Less concerning ifQ2 total revenue growth meets or exceeds 22% year over year.
Why it matters: Better cash flow from operations helps Halozyme grow and spend money wisely. This is important for future investments.
Supportive ifCash from operations was higher than last quarter.
Worry ifCash from operations is lower than last quarter.
Why it matters: New approvals would increase future royalty revenue. They would also show Halozyme's pipeline is strong.
Supportive ifAnnouncement of at least one new ENHANZE product approval by the end of 2026.
Worry ifNo new ENHANZE product approvals announced by the end of 2026.
Why it matters: Updates from the new CFO could signal changes in financial strategy. This may impact revenue and operating income.
Supportive ifA press release or statement about new money plans from the CFO.
Worry ifNo significant updates or changes in strategy from the CFO in the next quarter.
Why it matters: Earnings results will show if Halozyme is on track to meet its revenue and profit guidance for 2026.
Watch forQ2 2026 total revenue meets or exceeds guidance of $1.710 billion to $1.810 billion.
Also watch forQ2 2026 total revenue falls below the guidance range.
Why it matters: If they meet or beat guidance, it shows strong growth. It also supports management's plan.
Supportive ifTotal revenue for 2026 reported within the range of $1.710 to $1.810 billion.
Worry ifTotal revenue falls below $1.710 billion for 2026.
Why it matters: Royalty revenue growth is key to Halozyme's financial health. A drop signals potential issues.
Worry ifQ3 royalty revenue growth falls below 41% year over year.
Less concerning ifQ3 royalty revenue growth meets or exceeds 43% year over year.
Why it matters: New partnerships can help make more money. Fewer deals may show less market interest.
Supportive ifAnnouncement of two or more new ENHANZE collaborations in Q3.
Worry ifNo new ENHANZE partnerships were announced in Q3.
Why it matters: Updates on share buybacks can show management's trust in the stock and finances.
Supportive ifAnnouncement of share repurchases totaling at least $100 million by the end of Q3.
Worry ifNo updates on share buybacks or lower buyback amounts.